Efficacy and Safety of Immunomodulators in Patients with COVID-19: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials

Journal article

Tracing back to Dec. 2019 when the first case of Novel Corona Virus disease was reported, the global community is still living in fear of Covid-19 disease due to repeatedly emerging new variants of SARS-CoV2. Even the vaccines developed till date cannot fully prevent the spread of this highly contagious disease posing significant global health burden. In such devastating times Ayurveda system of medicine is a beacon of hope for thousands of people. Ayush-64 is an Ayurvedic formulation which was developed by the Central Council for Research in Ayurvedic Sciences (CCRAS), Ministry of AYUSH and Govt. of India for the management of Malaria. It has four ingredients having immunomodulatory, febrifugal, anti-oxidant and antiviral activities. The experimental studies done on Ayush-64 showed that its phytoconstituents have high binding affinity against Covid-19 virus. Therefore, it has also been encompassed in the National Covid management protocol based on Ayurveda and Yoga by GOI for asymptomatic, mild, moderate cases of Covid-19. The potential of Ayurveda has been already seen worldwide during pandemic times. This is our humble attempt to explore the effect of Ayush-64 in Covid-19

Authors: Ngamprasertchai, T; Kajeekul, R; Sivakorn, C; Ruenroegnboon, N; Luvira, V

• Publication status: Published
• Peer review status: Peer reviewed
• Publisher: Springer
• Journal: Infectious Diseases and Therapy
• Volume: 11
• Issue: 1
• Pages: 231-248
• Publication date: 2021-11-10
• DOI: 10.1007/s40121-021-00545-0
• EISSN: 2193-6382
• ISSN: 2193-8229
• Language: English
• Keywords: Meta-analysis; Ruxolitinib; Internal medicine; Medicine; Clinical trial; Randomized controlled trial